Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 15 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/1/2008 First Published: 5/5/2006


1.		Phase III Randomized Study of Percutaneous Isolated Hepatic Arterial Perfusion With Melphalan With Subsequent Venous Hemofiltration Versus Best Alternative Standard Treatment in Patients With Unresectable Liver Metastases Secondary to Ocular or Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				NCI-06-C-0088 NCI-P6701, NCT00324727


2.		Lucentis as an Adjuvanct Therapy With TTT-ICG Based in Choroidal Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 90				Other				FVF4290s NCT00680225

Last Modified: 9/19/2007 First Published: 4/7/2006


3.		Phase I/II Randomized Study of Vaccination Comprising MART-1/gp100/Tyrosinase/NY-ESO-1/MAGE-3 Peptide-Pulsed Dendritic Cells Matured Using Cytokines in Combination With Autologous Lymphocyte Infusion With or Without Fludarabine in Patients With Chemotherapy-Naïve Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				16 and over				NCI				MCC-13649 LAC-USC-10M-05-2, 6241, NCI-6241, LAC-USC-HS-05-00068, NCT00313508

Last Modified: 11/26/2007 First Published: 5/28/2004


4.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MCC-15241 MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036

Last Modified: 2/20/2008 First Published: 7/15/2005


5.		Phase II Study of Vorinostat (SAHA) in Patients With Metastatic or Unresectable Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				PMH-PHL-040 NCI-6916, 6916, NCT00121225

Last Modified: 8/16/2008 First Published: 3/2/2007


6.		Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				Other				MSKCC-05122 NCT00445965

Last Modified: 5/22/2008 First Published: 3/16/2007


7.		Phase II Study of VEGF Trap in Patients With Recurrent Inoperable Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CCC-PHII-77 7522, NCT00450255

Last Modified: 7/17/2007 First Published: 6/15/2007


8.		Phase II Pilot Study of Adjuvant Sunitinib Malate, Tamoxifen Citrate, and Cisplatin in Patients With High-Risk Ocular Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				POHA-0604 06-04, NCT00489944


9.		Study of Ipilimumab to Treat Melanoma in Patients With Brain Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				Pharmaceutical / Industry				CA184-042 NCT00623766


10.		Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Other				P2 10140402 R21CA103250, NCT00661622

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute